I share your frustration in this regard. But one of the things that other posters brought to my attention is that there are limitations on what a PR company can do with a drug that is not approved by the FDA.

I think this is one of many things that change, once we have an approval. We're hoping that the mild/moderate trial concludes mid June, and we get an approval shortly thereafter. The conclusion of the trial, and the days and weeks that immediately follow will shine a bright light on Leronlimab.